Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52
Keyword(s):
B 52
◽
2017 ◽
Keyword(s):
2014 ◽
Vol 32
(15_suppl)
◽
pp. 506-506
◽
Keyword(s):
2018 ◽
Vol 24
(21)
◽
pp. 5292-5304
◽
2015 ◽
Keyword(s):